Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Introduction: Patients with multiple myeloma (MM) are at ongoing risk of financial toxicity (FinTox) from medication costs and lost productivity (Richter CLML 2020, Fiala CLML 2023). Given MM's incurable nature with ongoing monitoring and supportive care, time toxicity (TimeTox) from frequent healthcare interactions may persist into the maintenance phase as well. The prevalence, predictors, and impact of FinTox and TimeTox on QOL have not been fully characterized in this population.